Dronabinol Market size is estimated to reach $351.3 million by 2027, growing at a CAGR of 6.7% during the forecast period 2022-2027. The growth of the Dronabinol Market is greatly influenced by the numerous medical advantages of Dronabinol to consumers. Dronabinol Is extensively utilized in the treatment of anorexia related to weight loss for those diagnosed with Acquired Immune Deficiency Syndrome (AIDS). Dronabinol is utilized in the treatment of vomiting related to patients of cancer chemotherapy who have not sufficiently responded to the traditional antiemetic treatments. Dronabinol is good for appetite invigoration in patients with the lethal HIV (Human Immunodeficiency Viruses) infection. The maximum dose of Oral solution of Dronabinol is 12.6 mg/m2 per dose.
For More Queries About "Dronabinol Market " @ https://www.industryarc.com/support.php?id=511936
Dronabinol Market Growth Drivers:
Stipulated Application of Dronabinol is Driving the Growth of the Dronabinol Industry:
All directions on the prescription label need to be followed and all medication guides or instruction sheets need to be read. The physician may occasionally alter the dose. The medication needs to be utilized exactly as directed. The physician needs to be informed if there is a raised longing to utilize more of this medication. To encourage appetite in people with AIDS, dronabinol is normally consumed 1 hour before lunch and 1 hour before dinner. To avert nausea and vomiting brought about by chemotherapy, the first dose needs to be consumed on an empty stomach, at least 30 minutes before eating. After the first dose, dronabinol may be consumed with or without food. However, it needs to be taken the same way every time. Dronabinol is mostly given 1 to 3 hours before chemotherapy treatment and then every 2 to 4 hours (up to 6 doses per day). The stipulated application of Dronabinol is therefore driving the growth of the Dronabinol Industry, thereby contributing to the Dronabinol Industry Outlook.
Utilization of Dronabinol in the Treatment of Moderate to Serious Obstructive Sleep Apnea (Off-label) is Propelling the Growth of the Dronabinol Market:
Dronabinol may be utilized in the treatment of moderate to serious obstructive sleep apnea (off-label). The oral dosage is 2.5 mg or 10 mg 1 hour before bedtime. An initial dose escalation is needed for the 10 mg dose. The dose needs to be introduced at 2.5 mg 1 hour before bedtime for 7 days and then 10 mg 1 hour before bedtime. The utilization of Dronabinol in the treatment of moderate to serious obstructive sleep apnea (off-label) is propelling the growth of the Dronabinol Market.
In April 2021, Merck declared financing of EUR 20 million to extend research and development and manufacturing possibilities at its site in Shizuoka, Japan. As a part of this plan, novel infrastructure would be erected to progress and expedite innovations in the electronic materials space.
Dronabinol Market: Competitive Landscape
Key companies holding major shares in the Dronabinol Market are LGC Group, Merck & Co., Inc., Alfa Chemistry, Aurora Fine Chemicals, ZINC, ChemSpace, Avantor, ChemFaces, Insys and Noramco.
To request for a quote, provide your details in the below link:
Mr. Venkat Reddy
Email: [email protected]
Contact Sales: +1-970-236-3677
About IndustryARC: IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food and Beverages, Information Technology, and Life sciences and Healthcare